A predominant cleaved form of pro-glucagon found in the pancreas and central nervous system. It has been reported that human pancreatic endocrine tumours contain molecular forms of GLP-1 which resemble those expressed in the small intestine, rather than in their tissue of origin. Within the CNS, GLP-1 powerfully inhibits feeding in fasting rats, an action which is blocked by prior administration of the GLP-1 receptor antagonist exendin [9-39]. This observation led to the suggestion that central GLP-1 is a physiological mediator of satiety and has projected GLP-1 into the obesity control debate. Glucagon-like peptide (GLP) 1 [1-36] also serves as a control peptide for Anti-Glucagon-like Peptide (GLP) 1 (BML-GA1176). Blocks immunoreactivity at 10 nmol per ml diluted antibody.
Product Details
| Alternative Name: | GLP 1 (1-36) amide, Blocking peptide for Glucagon like peptide 1 pAb (Prod. No. BML-GA1176) |
| |
| Sequence: | H-His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-amide |
| |
| MW: | 4111.5 |
| |
| Purity: | ≥95% |
| |
| Appearance: | Lyophilized solid. |
| |
| Solubility: | Soluble in water at 1mg/mL. |
| |
| Shipping: | Blue Ice |
| |
| Long Term Storage: | -20°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Related Products
